天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

ChemicalBook--->CAS DataBase List--->331731-18-1

331731-18-1

331731-18-1 Structure

331731-18-1 Structure
IdentificationBack Directory
[Name]

Unii-fys6T7F842
[CAS]

331731-18-1
[Synonyms]

D2E7
Humira
LU200134
Adalimumab
Unii-fys6T7F842
Adalimumab Beta
Unii-fys6T7F842 USP/EP/BP
Adalimumab (anti-TNF-alpha)
Immunoglobulin G1, anti-(human tumor necrosis factor) (human monoclonal D2E7 heavy chain), disulfide with human monoclonal D2E7 light chain, dimer
[EINECS(EC#)]

604-279-5
[Molecular Formula]

C6428H9912N1694O1987S46
[MDL Number]

MFCD00162116
[MOL File]

331731-18-1.mol
[Molecular Weight]

434.463
Chemical PropertiesBack Directory
[storage temp. ]

Store at -80°C
[form ]

Liquid
[color ]

Colorless to light yellow
Safety DataBack Directory
[Hazardous Substances Data]

331731-18-1(Hazardous Substances Data)
Hazard InformationBack Directory
[Description]

Adalimumab (CAS: 331731-18-1) is the first fully human neutralizing IgG1 monoclonal antibody specific for TNF-alpha and is the third TNF sequestrant marketed. It was launched in US, UK and Germany for the treatment of rheumatoid arthritis. It prevents TNF binding to p55 and p75 cell surface TNF receptors thereby decreasing leukocyte migration and acute phase reactants such as C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and levels of serum IL-6, MMP-1 and MMP-3. Adalimumab was developed starting with a phage-display derived murine antibody, followed by replacement of both heavy and light chains with human forms and further optimization to yield the final humanized form. In receptor binding studies, adalimumab exhibits an IC50 between 7.8×10-11 and 15.6×10-11M with a Kd of 1×10-10 M. It also binds to pro-TNFalpha on cell membranes mediating complement-dependent toxicity and to the Fc receptor mediating antibody-dependent cytotoxicity. In a human-TNF transgenic polyarthritis mouse model, adalimumab was efficacious based upon both clinical and histological readouts. Patients responding inadequately to methotrexate were co-administered methotrexate and adalimumab, which resulted in improved ACR scores in a 52-week study (ACR20: 59%; ACR50: 42%; ACR70; 23%). Radiographic analysis at six months showed decreased progression of structural joint damage (96%>placebo) and that joint-space narrowing stabilizes after six months. Adalimumab has an ED50 of 0.3 to 0.5 mg/kg and is dosed subcutaneously once every two weeks (0.8 mL containing 40 mg). The Vdss ranged from 0.063 to 0.76 L/kg consistent with being highly localized within the vasculature. It is slowly cleared with clearance values ranging from 0.18 to 0.27 mL/min and with a terminal half-life of about 12 days. As is the case with other TNF-alpha sequestrants, injection-site irritation is the most common side effect. The risk of developing opportunistic infection, especially tuberculosis, has been noted with TNF sequestrant biologics, which has led to screening of patients to identify those at risk.
[Originator]

Cambridge antibody technology (US)
[Uses]

Treatment of rheumatoid arthritis and other chronic inflammatory diseases (monoclonal antibody).
[Definition]

ChEBI: Sivelestat is a N-acylglycine and a pivalate ester. It is functionally related to a N-benzoylglycine.
[Indications]

Adalimumab has been evaluated in a number of clinical trials for RA, Crohn's disease,ankylosing spondylitis,and psoriatic arthritis. Initially evaluated as adjunctive therapy to RA patients on methotrexate, adalimumab demonstrated rapid improvement in American College of Rheumatology 20 scores at 1 week of administration. The PREMIER trial compared combination adalimumab plus methotrexate therapy with either medication given alone and found that the combination of adalimumab plus methotrexate was superior to adalimumab or methotrexate monotherapy.
[Brand name]

Humira
[Pharmacology]

Adalimumab is a fully human, anti-TNF-α IgG1 monoclonal antibody, which blocks the interaction of TNF-α with p55 and p75 cell surface receptors.
Adalimumab is typically administered as a 20-or 40-mg dose via subcutaneous injection either weekly or every other week. The subcutaneous route of administration may be favorable to infliximab, which requires an intravenous infusion.
The terminal half-life of adalimumab ranges from 15 to 19 days and early phase I trials demonstrated no significant pharmacokinetic advantage to weight-based dosing strategies.
[Clinical Use]

Adalimumab is supplied in single-use, prefilled, glass syringes as a sterile, preservative-free, colorless solution for subcutaneous administration. The pharmacokinetics of adalimumab were linear over the dose range of 0.5 to 10.0 mg/kg following a single IV dose. The mean elimination half-life was approximately 2 weeks.
[Side effects]

Injection site reactions appear to be the most commonly reported adverse event and occur in up to 10% of patients treated. In an efficacy and safety study of adalimumab for ankylosing spondylitis, the number of adverse events was higher in patients receiving subcutaneous adalimumab 40 every other week than in those receiving placebo. The percentage of patients who experienced infectious complications was higher in the patients receiving adalimumab, but this finding was not statistically significant. No occurrences of latent tuberculosis reactivation, lupus-like syndromes, congestive heart failure, or secondary malignancies were reported.In a postmarketing surveillance study of RA patients, Schiff et al.reported that adalimumab appeared to be relatively safe and well tolerated. In their study, safety data from randomized clinical trials, open-label extensions, phase IIIb trials, and postmarketing reporting of adverse events in the USA were collected. Reported adverse events included serious infections (5.1 events/100 patient-years (PYs)), lymphoma (0.12/100 PYs), tuberculosis (0.27/100 PYs), opportunistic infections (0.08 events/100 PYs), demyelinating diseases (0.08/100 PYs), systemic lupus erythematosis/lupus-like syndrome (0.10/100 PYs), and congestive heart failure (0.28/100 PYs). The incidence of lymphoma did not appear to be significantly higher in patients treated with adalimumab than in RA patients who were naïve to anti-TNF-α therapy; however, the rate of lymphoma may be higher in RA patients compared to the general population, particularly in patients with severe RA. Adverse events reported in patients with ophthalmic inflammatory disease treated with adalimumab have included injection site reactions, herpes simplex keratitis, and elevation of liver enzymes requiring cessation of therapy.
[Enzyme inhibitor]

This widely used human monoclonal antibody (Mol. Wt. = 144,190.3 kDa; CAS 331731-18-1; bioavailability = 64% Subcutaneous; Half-life = 10-20 days), known commercially as Humira, is used in the treatment of autoimmune diseases by blocking the action of the soluble pro- inflammatory cytokine, tumor necrosis factor, or TNF. Adalimumab and four other anti-TNF agents (infliximab, etanercept, golimumab and certolizumab pegol) are approved worldwide for the treatment of rheumatoid arthritis. These anti-TNF agents bind to and neutralize soluble TNF-alpha, exerting different effects on transmembrane TNF-alpha- expressing cells. Differences in affinity and avidity for soluble and transmembrane TNF-alpha have been demonstrated.
[Drug interactions]

Adalimumab is currently approved for RA and psoriatic arthritis in combination with methotrexate and low-dose prednisone. Live viruses should be avoided in patients on adalimumab and its use may decrease the immunologic protection conferred by live attenuated vaccines. No clear data are available for its use in combination with other biologic agents, so this combination should be avoided until further studies have demonstrated efficacy and safety.
[Metabolism]

Most likely removed by opsonisation via the reticuloendothelial system.
[Precautions]

Adalimumab is contraindicated in patients with known hypersensitivity to the medication or any of its components and in patients at risk for sepsis. In addition, the medication should be avoided in patients with a history of multiple sclerosis, active infection, or malignancy.
331731-18-1 suppliers list
Company Name: Shanghai Minbiotech Co., Ltd.
Tel: +8617315815539 , +8617315815539
Website: www.approvedhomemanagement.com/ShowSupplierProductsList516870/0.htm
Company Name: Henan Tianfu Chemical Co.,Ltd.
Tel: +86-0371-55170693 +86-19937530512 , +86-19937530512
Website: https://www.tianfuchem.com/
Company Name: Hubei xin bonus chemical co. LTD
Tel: 86-13657291602
Website: www.approvedhomemanagement.com/ShowSupplierProductsList1549548/0.htm
Company Name: TopScience Biochemical
Tel: 00852-68527855
Website: www.approvedhomemanagement.com/ShowSupplierProductsList892930/0.htm
Company Name: career henan chemical co
Tel: +86-0371-86658258 +8613203830695 , +8613203830695
Website: www.coreychem.com
Company Name: TargetMol Chemicals Inc.
Tel: +1-781-999-5354 +1-00000000000 , +1-00000000000
Website: https://www.targetmol.com/
Company Name: Hubei Ipure Biology Co., Ltd
Tel: +8613367258412 , +8613367258412
Website: www.ipurechemical.com
Company Name: HONG KONG IPURE BIOLOGY CO.,LIMITED
Tel: 86 18062405514 18062405514 , 18062405514
Website: www.approvedhomemanagement.com/ShowSupplierProductsList1523002/0_EN.htm
Company Name: Shanghai UCHEM Inc.
Tel: +862156762820 +86-13564624040 , +86-13564624040
Website: http://www.myuchem.com/
Company Name: Dideu Industries Group Limited
Tel: +86-29-89586680 +86-15129568250 , +86-15129568250
Website: https://www.dideu.com
Company Name: AFINE CHEMICALS LIMITED
Tel: +86-0571-85134551
Website: www.afinechem.com/index.html
Company Name: Wuhan Fortuna Chemical Co., Ltd
Tel: +86-027-59207850
Website: www.fortunachem.com/
Company Name: Baoji Guokang Healthchem co.,ltd
Tel: +8615604608665 15604608665 , 15604608665
Website: www.gk-bio.com
Company Name: Hefei Hirisun Pharmatech Co., Ltd
Tel: +8615056975894 , +8615056975894
Website: www.hirisunpharm.com
Company Name: Zhejiang J&C Biological Technology Co.,Limited
Tel: +1-2135480471 +1-2135480471 , +1-2135480471
Website: https://www.sarms4muscle.com
Company Name: Hangzhou Huarong Pharm Co., Ltd.
Tel: 571-86758373 +8613588754946 , +8613588754946
Website: https://www.huarongpharm.com/
Company Name: Wuhan Golt Biotech Co., Ltd.
Tel: +8615389281203 , +8615389281203
Website: www.goltbiotech.com
Company Name: LEAP CHEM CO., LTD.
Tel: +86-852-30606658
Website: www.leapchem.com
Tags:331731-18-1 Related Product Information
815610-63-0 946414-94-4 216974-75-3 945721-28-8 242138-07-4 1374853-91-4 923950-08-7 170277-31-3 174722-31-7 632-69-9 1380723-44-3 615258-40-7 205923-56-4 1256937-27-5 947687-13-0 477202-00-9 219685-50-4